Clinical Trial Detail

NCT ID NCT02364609
Title Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of California, Davis
Indications

lung non-small cell carcinoma

Therapies

Afatinib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.